Classic biostatistics, a branch of statistical science, has as its main focus the applications of statistics in public health, the life sciences, and the pharmaceutical industry. Modern biostatistics, beyond just a simple application of statistics, is a confluence of statistics and knowledge of multiple intertwined fields. The application demands, the advancements in computer technology, and the rapid growth of life science data (e.g., genomics data) have promoted the formation of modern biostatistics. There are at least three characteristics of modern biostatistics: (1) in-depth engagement in the application fields that require penetration of knowledge across several fields, (2) high-level complexity of data because they are longitudinal, incomplete, or latent because they are heterogeneous due to a mixture of data or experiment types, because of high-dimensionality, which may make meaningful reduction impossible, or because of extremely small or large size; and (3) dynamics, the speed of development in methodology and analyses, has to match the fast growth of data with a constantly changing face. This book is written for researchers, biostatisticians/statisticians, and scientists who are interested in quantitative analyses. The goal is to introduce modern methods in biostatistics and help researchers and students quickly grasp key concepts and methods. Many methods can solve the same problem and many problems can be solved by the same method, which becomes apparent when those topics are discussed in this single volume.

The Society of Environmental Geochemistry and Health (SEGH) Second International Conference on Arsenic Exposure and Health Effects was held June 12-14, 1995 in San Diego, California. The conference was at tended by 152 people who heard 41 presentations on all aspects of arsenic research. The speakers represented 14 countries. Approximately 40 of the participants and speakers were from countries other than the US. The participants represented government, academia, industry and the interested public. The sponsorship ofthe conference is a good indicationofthe wide spread interest in the subject and the meeting. The sponsors, in addition to SEGH, were the US Environmental Protection Agency (US EPA), the Agency for Toxic Substances and Disease Registry (ATSDR), the Atlantic Richfield Company (ARCO), the Electric Power Research Institute (EPRI), the American Water Works Association Research Foundation (AWWARF), Kennecott Corporation, the American Smelting and Refining Company (ASARCO), and the International Council on Metals in the Environment (ICME). The funding was split approximately equally between industry (including industrial organizations such as EPRI) and government. In addition to the many fine presentations, the meeting provided a forum for scientists from different countries to compare experiences and share information. It also provided a forum for the discussion of both scientific and policy issues between representatives of various governmental bodies (at the local, state, and federal level) and representatives of various indus trial organizations. These discussions occurred both in the formal meetings and informal settings during the meeting.

Drug-related problems in the elderly is intended to serve as a source of information and clinical support in geriatric pharmacotherapy for students as well as all health care professionals, e.g. physicians, nurses and pharmacists. Pharmacotherapy is of great importance to all mankind. Drugs are however powerful and must be handled appropriately. This is especially important for elderly patients. Drug-related problem is not a major subject in most university programmes in medicine or pharmacy. When there is no speci c course, there is often no book covering the topic. In our view, as teachers at various university courses, there has been a shortage of literature that re ects the most important aspects of drug-related problems in the elderly. Medical practitioners, nurses and pharmacists, need to have this knowledge to be able to serve their patients in the best way. This book covers most aspects of drug-related problems in the elderly. With b- ter knowledge of drug-related dif culties and risks we hope that elderly will have fewer drug-related problems and bene t more from their pharmacotherapy.

A major challenge confronting the pharmaceutical scientist working with protein formulation is the instability during processing, storage and use of the protein drug. This book reviews stability aspects encountered since the pioneering isolation of insulin in 1921. An introductory chapter, treating insulin purity and stability in historical perspective, is followed by a chapter with a description of the structure of insulin. The main part of the book is a comprehensive review of the literature dealing with stability of insulin in pharmaceutical formulation, including biological stability and the physical and chemical decomposition of insulin. The physical stability (i.e. the tendency of insulin to form insoluble fibrils) is reviewed as are methods to stabilize insulin for long-term use in infusion pumps. The book will be of interest to research and clinical pharmacologists involved with insulin and other protein-based drug substances.

This book brings together most up-to-date information on different aspects of brain aging and on the strategies for intervention and therapy of age-related brain disorders. It includes 18 chapters by leading researchers, and each chapter is a comprehensive and critical review of the topic in question, discusses the current scenario and focuses on future perspectives. The target readership is the undergraduate and graduate students in the universities, in medical and nursing colleges, along with the post-graduate researchers and practicing clinicians who would like to know about the latest developments in the field of neurodegenerative disorders and their therapeutic interventions. This book will be of much interest to pharmaceutical, nutrition and healthcare industry for an easy access to accurate and reliable information in the field of aging research and intervention.

The fact that tobacco ingestion can affect how people feel and think has been known for millennia, placing the plant among those used spiritually, honori?cally, and habitually (Corti 1931; Wilbert 1987). However, the conclusion that nicotine - counted for many of these psychopharmacological effects did not emerge until the nineteenth century (Langley 1905). This was elegantly described by Lewin in 1931 as follows: "The decisive factor in the effects of tobacco, desired or undesired, is nicotine. . . "(Lewin 1998). The use of nicotine as a pharmacological probe to und- stand physiological functioning at the dawn of the twentieth century was a landmark in the birth of modern neuropharmacology (Limbird 2004; Halliwell 2007), and led the pioneering researcher John Langley to conclude that there must exist some "- ceptive substance" to explain the diverse actions of various substances, including nicotine, when applied to muscle tissue (Langley 1905). Research on tobacco and nicotine progressed throughout the twentieth century, but much of this was from a general pharmacological and toxicological rather than a psychopharmacological perspective (Larson et al. 1961). There was some attention to the effects related to addiction, such as euphoria (Johnston 1941), tolerance (Lewin 1931), and withdrawal (Finnegan et al. 1945), but outside of research supported by the tobacco industry, addiction and psychopharmacology were not major foci for research (Slade et al. 1995; Hurt and Robertson 1998; Henning?eld et al. 2006; Henning?eld and Hartel 1999; Larson et al. 1961).

Medicinal chemistry is both science and art. The science of medicinal chemistry offers mankind one of its best hopes for improving the quality of life. The art of medicinal chemistry continues to challenge its practitioners with the need for both intuition and experience to discover new drugs. Hence sharing the experience of drug research is uniquely beneficial to the field of medicinal chemistry. Drug research requires interdisciplinary team-work at the interface between chemistry, biology and medicine. Therefore, the topic-related series Topics in Medicinal Chemistry covers all relevant aspects of drug research, e.g. pathobiochemistry of diseases, identification and validation of (emerging) drug targets, structural biology, drugability of targets, drug design approaches, chemogenomics, synthetic chemistry including combinatorial methods, bioorganic chemistry, natural compounds, high-throughput screening, pharmacological in vitro and in vivo investigations, drug-receptor interactions on the molecular level, structure-activity relationships, drug absorption, distribution, metabolism, elimination, toxicology and pharmacogenomics. In general, special volumes are edited by well known guest editors.

Sildenafil, for the treatment of erectile dysfunction, is one of the first products that has made its way successfully from basic NO (nitrous oxide) research, to clinical routine therapy. Sidenafil, part of the Milestones in Drug Therapy series, presents the major breakthroughs in the field of NO physiology and pharmacology that led to the development of the drug, as well as clinical applications in one source guide.

Written by leading experts in the field, each chapter covers aspects of clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and cultural science.

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980's with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due to early studies in the mouse skin carcinogenesis model, which showed that prolonged topical application of phorbol esters promoted the formation of skin tumors on mice previously treated with mutagenic agents. Research in the last years has established key roles for PKC isozymes in the control of cell proliferation, migration, adhesion, and malignant transformation. In addition, there is a large body of evidence linking PKC to invasion and cancer cell metastasis. Moreover, it is now well established that the expression of PKC isozymes is altered in various types of cancers. More importantly, small molecule inhibitors have been developed with significant anti-cancer activity. The relevance of PKC isozymes in cancer signaling is therefore remarkable. This book will have 4 sections. There will be 23 chapters. Each section will have a brief introduction by an expert in the field (~ 1-2 pages).

Endocannabinoids have tremendous therapeutic potential. This book introduces readers to our current understanding of the neurobiology of endocannabinoids and related systems, detailing their pathophysiological role and therapeutic potential. Authors, experienced clinical investigators, present and analyze results of recent clinical trials as well as the development of new therapeutic strategies and medicines.

The idea for this book came from discussions among participants in a symposium on biotechnical applications at the "Pacifichem 89" meeting in Honolulu. It was the majority opinion of this group that a volume dedicated to biotechnical and biomedical applications of PEG chemistry would enhance research and development in this area. Though the book was conceived at the Honolulu meeting, it is not a proceedings of this symposium. Several groups who did not participate in this meeting are repre sented in the book, and the book incorporates much work done after the meeting. The book does not include contributions in all related areas to which PEG chemistry has been applied. Several invited researchers declined to parti.: ipate, and there is not enough space in this single volume to properly cover all submissions. Chapter I-an overview of the topic-discusses in brief applications not given detailed coverage in specifically devoted chapters. The following topics are covered: introduction to and fundamental properties of PEG and derivatives in Chapters 1-3; separations using aqueous polymer two-phase partitioning in Chapters 4-6; PEG-proteins as catalysts in biotechnical applications in Chapters 7 and 8; biomedical applications of PEG-proteins in Chapters 9-13; PEG modified surfaces for a variety of biomedical and biotechnical applications in Chapters 14-20; and synthesis of new PEG derivatives in Chapters 21 and 22."

This publication represents the result of the fruitful workshop organised with the aim to attract the attention on the possibility of bio terrorism attack, with the s- port of NATO funds. In the last years the attention was strongly concentrated on the terrorism view similar to "military type attacks: " bomb on the trains, kamikazes, airplanes etc. As consequence many devices studied are directed to prevent these attacks such as the control of the passengers before the flight. For the people terrorism is therefore equivalent to bomb or similar and nobody think that there is also other possible and sophisticated means that can be used by the terrorist. In 1995 Sarin gas in the Tokio subway killed 12 people and affected 5,000 persons. In the USA anthrax was sent by mail to many federal offices. These events and other cases attract the attention on these possible terrorist attacks and the first recommendations for preventing theses events were\elaborated in the United State and in Europe. The possible agents and the modality that can be used for the diffusion are analysed and food and water are considered the principal and more favourable way. The story and the principal decision about this were reported in the first article of this collection which introduces the concept of bio-terrorism.

This book provides an overview of the etiology of coronary artery disease and focuses on the main therapies and drug interventions currently available. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease. The book is divided into eight chapters, the first of which describes the classical mechanism of coronary artery disease and its clinical presentations. Chapter 2 lists the principles of and related evidence on the prevention and treatment of coronary artery disease. This includes diet and lifestyle management, and guidelines for the treatment of acute coronary syndrome and stable coronary artery disease. In turn, Chapter 3 describes revascularization treatments, covering percutaneous coronary interventions, coronary artery bypass grafts and thrombolysis. This chapter also addresses the main therapeutic challenges. The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure constitutes the major health burden in the late stage of coronary artery disease; accordingly, current heart failure therapeutics and related drug pharmacology are described in Chapter 7. In closing, Chapter 8 provides a summary of on-going clinical trials for coronary artery disease drug development and discusses a number of promising areas in which intensive research into new therapeutics is being pursued. Given its scope, the book will be of interest to clinicians, medical students and research scientists, as well as to pharmaceutical professionals who are seeking new therapies and drugs for coronary artery disease and related disorders.

Ecotoxicology is a relatively new scientific discipline. Indeed, it might be argued that it is only during the last 5-10 years that it has come to merit being regarded as a true science, rather than a collection of procedures for protecting the environment through management and monitoring of pollutant discharges into the environment. The term 'ecotoxicology' was first coined in the late sixties by Prof. Truhaut, a toxicologist who had the vision to recognize the importance of investigating the fate and effects of chemicals in ecosystems. At that time, ecotoxicology was considered a sub-discipline of medical toxicology. Subsequently, several attempts have been made to portray ecotoxicology in a more realistic light. Notably, both Moriarty (1988) and F. Ramade (1987) emphasized in their books the broad basis of ecotoxicology, encompassing chemical and radiation effects on all components of ecosystems. In doing so, they and others have shifted concern from direct chemical toxicity to humans, to the far more subtle effects that pollutant chemicals exert on natural biota. Such effects potentially threaten the existence of all life on earth. Although I have identified the sixties as the era when ecotoxicology was first conceived as a coherent subject area, it is important to acknowledge that studies that would now be regarded as ecotoxicological are much older.

In this book, leading-edge investigators offer effective strategies to improve current antidepressive therapies and suggest molecular, biological, and genetic approaches that will lead to the development of novel antidepressants. The contributors' critical reviews and commentaries illuminate our understanding of the mechanism(s) responsible for antidepressant action. The book's goal is to move beyond current biogenic amine-based concepts and therapies to the development of new and improved antidepressants that are more effective and have a more rapid onset than current.

This book is based on the proceedings of the symposium entitled "Di rected Drug Delivery: A Multidisciplinary Problem," which was held in Lawrence, Kansas on October 17-19, 1984. The purpose of the sym posium and this book is to focus on the multidisciplinary nature of drug delivery. Development of a successful drug delivery system re quires contributions from various scientific disciplines, including pharmaceutical chemistry, analytical chemistry, medicinal chemistry, biochemistry, pharmacology, toxicology, and clinical medicine. The contents of this volume illustrate the importance of the various disci plines in identifying the problems and approaches for the develop ment of a rational and effective drug delivery system. Thus the infor mation provided herein will be of value not only to the pharmaceutical chemists who are responsible for dosage form design, but also to the pharmacokineticists, pharmacologists, and clinicians involved in bio logical evaluation of drug delivery systems. The volume should also be of interest to the analytical chemists who must provide technology to quantitcltively evaluate drug delivery. Additionally, this work will also interest the biochemists and medicinal chemists involved in drug dis covery, since the drug delivery system often plays a major role in determining the success or failure of a new drug entity. Each speaker at the symposium was requested to contribute a chapter reviewing the contribution of their major discipline to the de velopment of a successful drug delivery system."

Cocaine has been a socio-medical problem for centuries. In the United States, the first cocaine epidemic occurred between the 1880s and the 1920s. In the 1960s shortages of heroin as well as government programs to stop the smuggling of marijuana may have stimulated the use of cocaine as a substitute. With the development of crack, cocaine became available at a price that made it accessible to virtually anyone. Today, the long-term effects of crack are just beginning to be felt, especially among children born of users. Treatment of cocaine abuse has traditionally been non-pharmacological, although beginning with the 1980s, various drugs have been used to decrease cocaine craving. This bibliography contains more than 600 references, spanning a century of research and writing. Source publications, all of which are annotated, include books, articles, conference proceedings, dissertations, and government publications. The material is organized within four subject-oriented chapters, and alphabetically within each chapter. Author and subject indexes provide additional access. In addition, Miletich includes appendixes on common names for cocaine, videocassettes about the drug, and a timeline. The work will be of value to researchers as well as social workers, psychologists, and others working in the substance abuse field.

This new 12th edition of Dale and Appelbe's Pharmacy and Medicines Law is your guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. This edition has been extensively restructured and revised to include all the most recent changes to pharmacy laws and regulation.

Introducing Palliative Care is the ideal introductory text for training students in medicine and qualified healthcare professionals in the area of palliative care. The sixth edition has been fully revised in line with current practice and the latest edition of the Palliative Care Formulary (PCF7).

Paul H. Axelsen concisely summarizes all the essential medical data concerning the leading antimicrobials used in fighting infectious diseases and clearly illustrates their mechanisms of action. The agents described range from antibacterial and antifungal to antiparasitic and antiviral agents, and include immunomodulators and immunizing agents. For each drug discussed, the book allows rapid access to the essential facts concerning its structure and mechanism of action, the spectrum of its activity, its pharmacokinetics, its adverse effects, and its resistance. This book provides medical students, physicians, and allied health professionals with rapid access to the core principles of antimicrobial pharmacology, and a foundation for decisions about the use of antimicrobials in daily practice.